Federal Men's Health Office Stalls. What It Means for TRT
5/26/2026
5 min read
By The TRT Catalog
The State of Men's Health Act has bipartisan support but faces political headwinds. Here's what the proposed federal office means for testosterone access.
Key Takeaways: A bipartisan bill to create a federal Office of Men's Health has unprecedented institutional support but faces political headwinds that could delay it for years. The proposed office would not directly prescribe or regulate testosterone, but by elevating men's health as a federal priority it could accelerate parallel regulatory changes -- expanded FDA indications, potential descheduling, better insurance coverage -- that directly affect TRT access. In the meantime, the FDA has already moved to expand testosterone's approved uses, and qualified online clinics continue to offer evidence-based treatment under current regulations.
American men live 5.3 years less than women. They die by suicide at four times the rate. They account for the majority of cardiovascular disease and diabetes deaths. And until February 2026, no federal legislation had ever proposed doing something about it [1].
The State of Men's Health Act, introduced with bipartisan support, calls for a dedicated federal office modeled after the Office of Women's Health established in 1991. On May 22, STAT News reported that despite unprecedented momentum, the effort has stalled -- likely years from becoming reality [2].
For the millions of men navigating testosterone therapy, the question is practical: does any of this matter for getting treatment?
The short answer is yes, but not in the way most people expect.
What the Proposed Office Would Do
The State of Men's Health Act, sponsored by Rep. Troy Carter (D-LA) and Rep. Gregory Murphy (R-NC), proposes two concrete actions [1][2]:
A comprehensive federal report on the state of men's health, disaggregated by race, socioeconomic status, and geography
A permanent Office of Men's Health within HHS, with a mandate covering preventive screenings, cardiovascular risk detection, mental health awareness, and early identification of metabolic disease
The bill explicitly prohibits diverting funding from women's health programs, addressing the concern that has historically sunk men's health proposals [1].
What the office would not do is regulate or prescribe testosterone directly. That remains the FDA's domain. But by framing men's health as a federal priority with dedicated funding and data collection, it creates institutional infrastructure that supports the regulatory changes already underway.
The connection between a federal men's health office and TRT access is indirect but meaningful. Here is the chain:
1. Routine Testosterone Screening
The proposed office would prioritize preventive screenings and early identification of metabolic disease. Testosterone deficiency fits squarely within this mandate. Currently, most men discover they have low testosterone only after years of worsening symptoms, because routine testosterone screening is not part of standard preventive care.
A federal office with screening guidelines could move testosterone testing into the same category as cholesterol panels and blood glucose checks -- standard practice, not something men seek out only after hitting a wall.
2. Data That Drives Policy
One of the biggest obstacles to expanding TRT access is the lack of large-scale epidemiologic data on testosterone deficiency prevalence and treatment outcomes. The proposed office would fund exactly this kind of research.
A 2026 NHANES analysis already showed that low testosterone affects roughly 40% of men over 45. But these are isolated studies, not systematic federal surveillance. An office with a data mandate would build the evidence base that regulators and insurers need to justify expanded coverage.
3. Parallel FDA Action Is Already Happening
The most immediate policy changes are occurring at the FDA, independent of the men's health office:
December 2025: An FDA expert panel recommended removing testosterone's Schedule III controlled substance status and expanding approved indications to include age-related low testosterone
April 2026: The FDA announced a new potential indication for low libido in men with idiopathic hypogonadism, encouraging manufacturers to submit supplemental applications
A federal men's health office would amplify these efforts by providing institutional backing and sustained political will. Without it, each FDA action stands alone, vulnerable to shifting administrative priorities.
The Political Reality
Despite the strongest institutional support in decades, the State of Men's Health Act faces real obstacles [2]:
Bipartisan but fragile. The bill has four sponsors evenly split between parties, plus endorsements from the American Urological Association, the American Medical Association, and the American Nurses Association. But midterm election dynamics make legislators cautious about appearing to prioritize men's health over women's.
Executive vs. legislative path. HHS Secretary Robert F. Kennedy Jr. and Assistant Secretary Brian Christine have signaled support for creating a men's health initiative through executive action. But advocates -- burned by the closure of Biden-era offices on long COVID and health equity -- insist on the statutory route. Executive orders can be undone. Legislation is permanent.
Timeline. Mark Edney, chair of the American Urological Association's public policy committee, estimates the process will span "at least a couple of sessions and perhaps into a new administration" [2]. That means 2028 at the earliest for a fully operational office.
The economic argument. Men's excess mortality and morbidity costs federal and local governments over $140 billion annually, with approximately $160 billion more in private healthcare costs [1]. This is the number that moves legislators who otherwise see men's health as a low-priority issue.
What Is Brian Christine's Role?
Admiral Brian Christine brings a unique perspective to the HHS Assistant Secretary for Health position. As a urologist whose practice focused on male patients, he understands testosterone deficiency at a clinical level that previous appointees did not [1][3].
At the December 2025 FDA panel on testosterone, Christine highlighted specific disparities: male life expectancy running nearly seven years shorter than women's, men accounting for the majority of suicide deaths, and the systematic underscreening of conditions like hypogonadism [3].
His pledge to establish a "parallel track" to women's health within HHS is the first time a senior federal health official has explicitly linked men's health infrastructure to testosterone access policy.
What This Means for You Right Now
The federal men's health office is a long-term story. If you are experiencing symptoms of low testosterone today, you should not wait for legislation to catch up.
Current Access Is Already Expanding
The regulatory landscape for TRT is more favorable than at any point in the last decade:
Know the threshold. The Endocrine Society defines hypogonadism as total testosterone below 300 ng/dL on two separate morning draws with consistent symptoms [4].
Evaluate your options. If levels are confirmed low, evidence-based treatment through a qualified clinic is available now -- you do not need to wait for a federal office to validate what the clinical evidence already supports.
What to Watch For
Three developments in the next 12 to 18 months will have more immediate impact on TRT access than the men's health office:
FDA indication expansion: Whether manufacturers submit supplemental NDAs for the low-libido indication by the FDA's timeline
Descheduling progress: Whether the DEA and FDA move forward on removing testosterone from Schedule III
Insurance policy shifts: Whether major insurers update coverage policies to reflect the FDA's new labeling and expanded indications
The Bigger Picture
The State of Men's Health Act represents something more fundamental than any single policy change: the recognition that men's health has been systematically under-prioritized at the federal level for 35 years.
The Office of Women's Health, established in 1991, demonstrably improved women's health outcomes and research funding. Countries including Australia, the United Kingdom, Ireland, and Canada have implemented similar men's health initiatives with measurable results [1].
For testosterone therapy specifically, a federal men's health office would not prescribe treatment or change FDA regulations. But it would build the institutional foundation -- the data, the screening guidelines, the research funding, and the political will -- that makes every subsequent regulatory change more likely to happen and harder to reverse.
That is worth watching, even if it takes years.
References
STAT News. "Momentum builds for a federal office of men's health focused on disease prevention." March 12, 2026.
STAT News. "A federal office of men's health has never been closer, yet it's likely still years away." May 22, 2026.
Healthline. "Testosterone Replacement Therapy: FDA Panel Calls for Expanded Access." December 2025.
Bhasin S, et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline." Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744.
FDA. "FDA Takes Step Forward on Testosterone Therapy for Men." April 16, 2026.
The State of Men's Health Act is a bipartisan bill introduced in the U.S. House of Representatives in February 2026 by Rep. Troy Carter (D-LA) and Rep. Gregory Murphy (R-NC). It calls for a comprehensive federal report on men's health status and the creation of a dedicated Office of Men's Health within the Department of Health and Human Services, modeled after the Office of Women's Health established in 1991.
Will a federal men's health office make TRT easier to get?
Not directly or immediately. A federal men's health office would focus on broad public health priorities: preventive screenings, cardiovascular risk detection, mental health, and data collection. However, by elevating men's health as a policy priority and funding research into testosterone deficiency, it could accelerate ongoing regulatory changes like expanded FDA indications for testosterone, potential descheduling from Schedule III, and insurance coverage improvements. These downstream effects would meaningfully reduce barriers to TRT access over time.
What are the biggest barriers to TRT access right now?
The main barriers are regulatory and insurance-related. Testosterone remains a Schedule III controlled substance, which limits prescribing flexibility and creates stigma. FDA-approved indications currently cover only classical hypogonadism from specific medical conditions, not age-related testosterone decline, meaning most TRT prescriptions are technically off-label. Insurance coverage for off-label prescriptions is inconsistent. An FDA expert panel recommended removing Schedule III status and expanding indications in December 2025, but formal regulatory changes have not yet occurred.
Who is Brian Christine and why does he matter for TRT?
Admiral Brian Christine is a urologist who was sworn in as HHS Assistant Secretary for Health in late 2025. His clinical background in treating male patients makes him the most men's-health-focused person to hold this position. He introduced the FDA expert panel on testosterone therapy, highlighted that male life expectancy is nearly seven years shorter than women's, and has pledged to make establishing a men's health initiative a priority under HHS Secretary Robert F. Kennedy Jr.
When will a federal men's health office be established?
It is likely years away. While bipartisan support is the strongest it has been in decades, political obstacles remain. Advocates worry that an executive-created office could be dismantled by a future administration. The preferred path is statutory legislation, which takes longer but provides permanence. Mark Edney, chair of the American Urological Association's public policy committee, estimates the process will span at least a couple of congressional sessions and perhaps into a new administration.
